Nuclear magnetic resonance (NMR) spectroscopy of blood plasma provides simultaneous measurement of lipoprotein particle number, size distribution, and metabolic markers—enabling assessment of cardiovascular disease risk, insulin resistance, inflammatory status, and mortality risk from a single sample. This integrated approach captures mechanistic information about metabolic dysfunction that standard lipid panels miss, offering a more precise foundation for risk stratification and therapeutic decision-making.
Key Points
- NMR measures particle number and size, not just cholesterol concentration
- Single test simultaneously assesses cardiovascular, metabolic, and inflammatory status
- Particle metrics predict disease risk independent of conventional lipid values
Longevity Analysis
NMR blood analysis represents a shift from population-level risk categories toward individual metabolic phenotyping. By decoding what standard lipid panels obscure—particle size heterogeneity, inflammatory particle burden, and apoB-dependent atherogenicity—clinicians can identify mechanistic drivers of cardiometabolic decline before overt disease emerges. This specificity permits targeted intervention on the actual pathways driving risk rather than treating surrogate markers, fundamentally changing how early metabolic dysfunction is detected and monitored across the decades before clinical events.
Original published by Peter Attia MD, by Peter Attia.